Current understanding of AD pathophysiology and impact of amyloid-beta targeted treatments on biomarkers and clinical endpoints

Alzheimers Dement (N Y). 2022 Oct 20;8(1):e12361. doi: 10.1002/trc2.12361. eCollection 2022.

Authors

Ronald C Petersen¹, Ana Graf², Maria C Carrillo³, Christopher J Weber³

Affiliations

¹ Mayo Clinic Alzheimer's Disease Research Center Rochester Minnesota USA.
² Novartis Pharma AG Klybeckstrasse, 4057 Basel Basel Switzerland.
³ Alzheimer's Association Chicago Illinois USA.

No abstract available

Publication types

News